Healthcare

Canada: Acute Care EHR & Digital Health 2026-What’s Changing Now in Adoption, Implementation, Selection and Satisfaction – Black Book Research

New, Canada-wide evidence from a late-2025 pulse survey of 648 acute care stakeholders-plus a 2026-2030 buyer roadmap on interoperability-as-a-procurement-gate, data...

Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times – Open Nationwide and Worldwide with Participation Cost

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay...

ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture

UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech,...

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE...

error: Content is protected !!